Journals / Acta Orthopaedica et Traumatologica Turcica / 2007 / Cilt: 41 - Sayı: 4

Prognostic factors in patients with malignant fibrous histiocytoma of the extremities

Ekstremite yerleşimli malign fibröz histiyositomlu hastalarda prognostik faktörler

Pages
271–276
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Kaplan-Meier analysis showed an overall five-year survival rate of 61.5%, being 100% in low-grade tumors, and 28.2% in high-grade tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity.
📊
Key Findings & Data:Methods: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity.
💡
Conclusion & Impact:Kaplan-Meier analysis showed an overall five-year survival rate of 61.5%, being 100% in low-grade tumors, and 28.2% in high-grade tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Seyir · Histiyositom · iyi huylu fibröz

Abstract

Objectives: We evaluated prognostic factors in patients with malignant fibrous histiocytoma of the extremity. Methods: The study included 26 patients (22 males, 4 females; 15 patients < age 60) with a diagnosis of malignant fibrous histiocytoma of the extremity. Clinical and pathological data were analyzed including age, gender, affected extremity, presentation status (primary or recurrent), localization (proximal or distal), size, depth, and grade of the tumor, resection quality, adjuvant therapy, and the presence of distant metastasis at the time of diagnosis. Results: The mean follow-up of 16 patients who were alive was 44.8 months (range 24 to 120 months). The mean symptom duration before diagnosis was seven months (range 1 to 26 months). All the patients underwent surgical resection. A margin-negative R0 resection was obtained in 17 patients. Amputation was performed in seven patients. Adjuvant chemotherapy and radiotherapy were administered to 17 patients and 10 patients, respectively. Local recurrence was detected in eight patients. Two patients had distant metastasis at the time of diagnosis while eight patients developed distant metastasis within a mean of 13 months (range 7 to 20 months) postoperatively. Kaplan-Meier analysis showed an overall five-year survival rate of 61.5%, being 100% in low-grade tumors, and 28.2% in high-grade tumors. Tumor grade was the only significant parameter affecting survival in both univariate (p=0.004) and multivariate (p=0.023) analyses. Conclusion: Patients with high-grade malignant fibrous histiocytoma have a poorer prognosis

Özet

Amaç: Ekstremite yerleşimli malign fibröz histiyositomlu olgularda prognostik faktörler araştırıldı. Çalışma planı: Çalışmada ekstremite yumuşak doku malign fibröz histiyositom tanısı konan 26 hasta (22 erkek, 4 kadın; 15 hasta <60 yaş) yaş, cinsiyet, tümörün durumu (primer veya nüks), etkilenen ekstremite, tümörün yerleşimi (proksimal veya distal), boyutu, derinliği, derecesi; rezeksiyon kalitesi, adjuvan tedavi ve tanı konduğunda uzak metastaz olması gibi sağkalımı etkileyebilecek faktörler açısından değerlendirildi. Sonuçlar: Hayatta olan 16 hastanın ortalama takip süresi 44.8 ay (dağılım 24-120 ay) idi. Tanı konmadan önceki ortalama semptom süresi yedi ay (dağılım 1-26 ay) idi. Tüm hastalara cerrahi rezeksiyon yapıldı. On yedi hastada geniş cerrahi sınır (R0) elde edildi. Toplam yedi hastada amputasyon yapıldı. On yedi hastaya adjuvan terapi, 10 hastaya radyoterapi uygulandı. Sekiz hastada lokal nüks gelişti. İki hastada tanı konduğunda uzak metastaz vardı. Takip sırasında sekiz hastada ortalama 13 ayda (dağılım 7-20 ay) uzak metastaz gelişti. Kaplan-Meier yöntemiyle hesaplanan beş yıllık sağkalım oranı %61.5 bulundu. Düşük dereceli tümörlerde beş yıllık sağkalım oranı %100 iken, yüksek dereceli tümörlerde bu oran %28.2 idi. Tekdeğişkenli (p=0.004) ve çokdeğişkenli (p=0.023) analizlerde tümör derecesi sağkalımı etkileyen tek parametre idi. Çıkarımlar: Malign fibröz histiyositomlu hastalarda yüksek dereceli tümör olması kötü prognoz göstergesidir. Anahtar sözcükler: Ekstremite; histiyositom, benign fibröz/tedavi; tümör metastazı; tümör nüksü, lokal; prognoz; radyoterapi, adjuvan; yumuşak doku neoplazileri/tedavi; sağkalım analizi.

🔖

Cite This Article

ATALAR, H., BAŞARIR, K., YILDIZ, H. Y., SAĞLIK, Y. (2007). Prognostic factors in patients with malignant fibrous histiocytoma of the extremities. Acta Orthopaedica et Traumatologica Turcica, Cilt: 41 - Sayı: 4, 271–276. https://ajindex.com/articles/354128

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Salo JC, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Malignant fibrous histiocytoma of the extremity. Cancer 1999;85:1765-72
  2. Bravo PA, Mena VD, Chicharro E. Malignant fibrous histiocytoma of bone treated by resection and prosthesis: a case report. Int Orthop 1983;7:105-11
  3. Huvos AG, Heilweil M, Bretsky SS. The pathology of malignant fibrous histiocytoma of bone. A study of 130 patients. Am J Surg Pathol 1985;9:853-71
  4. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 1996;77:1823-30
  5. Campanacci M, Bertoni F, Bacchini P, editors. Bone and soft tissue tumors. Notini S, translator. Translation of “Tumori delle ossa e delle parti molli”. New-York: Springer-Verlag; 1990. p. 885-901
  6. Peiper M, Zurakowski D, Knoefel WT, Izbicki JR. Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 2004;135:59-66
  7. Pritchard DJ, Reiman HM, Turcotte RE, Ilstrup DM. Malignant fibrous histiocytoma of the soft tissues of the trunk and extremities. Clin Orthop Relat Res 1993;(289):58-65
  8. Robert KH. Malignant tumors of bone. In: Canale ST, editor. Campbell’s operative orthopaedics. Vol, 1. 10th ed. St. Louis: Mosby; 2003. p. 827-58
  9. Akerman M. Malignant fibrous histiocytoma-the commonest soft tissue sarcoma or a nonexistent entity? Acta Orthop Scand Suppl 1997;273:41-6
  10. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Semin Diagn Pathol 1995;12:210-20
  11. Lee SY, Kim SS, Jeon DG, Baek GH. Malignant fibrous histiocytoma of the limbs. Int Orthop 1993;17:173-5
  12. Markhede G, Angervall L, Stener B. A multivariate analysis of the prognosis after surgical treatment of malignant soft-tissue tumors. Cancer 1982;49:1721-33
  13. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-75
  14. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. American Joint Committee on Cancer: Cancer staging manual. 6th ed. New York: Springer; 2002
  15. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41:2250-66
  16. Berlin O, Stener B, Angervall L, Kindblom LG, Markhede G, Oden A. Surge